Home monitoring of blood tests for cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to implement remote home monitoring of complete blood counts for cancer patients undergoing chemotherapy. By allowing patients to conduct blood tests at home, the study seeks to reduce unnecessary travel and associated costs, while improving patient involvement in their treatment. The research will evaluate the feasibility of this approach across multiple sites in the South Baltic region, focusing on the implementation process and potential changes in patient care pathways. The study will also assess the technology used for home monitoring and gather insights for future investigations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* legally competent patients
* aged 18 or older
* diagnosed with cancer (ICD-10: C00\* - C97\*)
* enrolled at the Department of Oncology/Hematology for outpatients
* participants who are willing and able to give informed consent for participation in the study
* participants should receive chemotherapy in Daily Chemotherapy Unit and be within 4 weeks of chemotherapy initiation, and the expected duration of chemotherapy should be at least 12 weeks from inclusion

Exclusion Criteria:

* inability to give informed consent due to mental capacity or language barrier
* patient unable or unlikely to be able to perform fine manipulation required to use lancet or cartridge to obtain capillary blood sample and result
* known bleeding disorder
* bad circulation preventing the patient from getting enough blood drops to perform the test

Where it's running

• Department of Oncology, Zealand University Hospital
  Næstved, Region Sjælland, Denmark Recruiting
• Clinic and Polyclinic for Internal Medicine C, Hematology and Oncology, Palliative Care Unit, University Medical Center
  Greifswald, Mecklenburg-Vorpommern, Germany Recruiting
• Department of Medicine, Clinic III, Hematology, Oncology, Palliative Medicine, University Medical Center
  Rostock, Mecklenburg-Vorpommern, Germany Recruiting
• Department of Oncology and Radiotherapy, University Clinical Center of Gdańsk,
  Gdansk, Pomeranian Voivodeship, Poland Recruiting
• Department of Hematology and Transplantology
  Szczecin, West Pomeranian Voivodeship, Poland Recruiting

Study contacts

• Principal investigator: Bogusław Machaliński, MD, PhD, Prof — Department of Hematology and Transplantology, Pomeranian Medical University in Szczecin
• Study coordinator: Bartłomiej Baumert, MD, PhD, DSc
• Email: bartlomiej.baumert@pum.edu.pl
• Phone: +48 91 4250428

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Me capegfilgrastim to help prevent neutropenia in advanced breast cancer patients on chemotherapy

  This real-world registry tests whether mecapegfilgrastim used with chemotherapy helps prevent low white blood cells in adults with advanced breast cancer.

  Recruiting Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT07899099

• Gait Changes in Breast Cancer Patients Receiving Chemotherapy

  This study tests how chemotherapy affects walking and balance in women with breast cancer.

  Recruiting Cairo University · Cairo, Cairo Governorate · NCT07894133

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• VR-guided mindfulness for anxiety, sleep, comfort, and fatigue in women with breast cancer undergoing chemotherapy

  This study tests whether a virtual reality–based mindfulness program can help women with breast cancer feel less anxious, sleep better, feel more comfortable, and have less fatigue during chemotherapy.

  Recruiting Hacettepe University · Ankara, Ankara · NCT07731477

• Romiplostim N01 plus ATRA for persistent chemotherapy-induced low platelets after remission from gynecologic, breast, or lung cancer

  This trial tests whether adding ATRA to Romiplostim N01 helps people keep a safe platelet count after finishing chemotherapy for certain cancers.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586826

• Romiplostim N01 plus ATRA for persistent low platelets after cancer remission

  This study tests whether adding all-trans retinoic acid to Romiplostim N01 helps people who still have low platelets after GI/digestive system cancer remission reach safer platelet levels.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07586813

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.